Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2025 | Tissue-selective estrogen complexes as a new treatment for DCIS

Swati Kulkarni, MD, Northwestern University Feinberg School of Medicine, Chicago, IL, comments on the significance of the PROMISE study (NCT02694809) of conjugated estrogen/bazedoxifene (CE/BZA) for ductal carcinoma in situ (DCIS). As it was a Phase II study, the study could not to make direct comparisons to tamoxifen or aromatase inhibitors. CE/BZA is a unique class of drugs, known as tissue-selective estrogen complexes (TSECs), which combine estrogen compounds with bazedoxifene, offering a new approach to hormone therapy. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So obviously ours is just a Phase II study. So obviously I always like to make sure I say that, that it’s a Phase II study and you’d need a much larger, longer term follow up to actually make that comparison to tamoxifen or aromatase inhibitors. But CE/BZA, I think just to say what it is, is it’s a combination of conjugated estrogens. So it’s actually estrogen compounds that have that’s that’s also an FDA approved drug, which I won’t mention, but it’s an FDA approved drug that’s made up of lots of different estrogen compounds that actually have different activity on the estrogen receptor...

So obviously ours is just a Phase II study. So obviously I always like to make sure I say that, that it’s a Phase II study and you’d need a much larger, longer term follow up to actually make that comparison to tamoxifen or aromatase inhibitors. But CE/BZA, I think just to say what it is, is it’s a combination of conjugated estrogens. So it’s actually estrogen compounds that have that’s that’s also an FDA approved drug, which I won’t mention, but it’s an FDA approved drug that’s made up of lots of different estrogen compounds that actually have different activity on the estrogen receptor. So some of those agents can act as SERMs. Some of them are inhibitory. Some of them are stimulatory. And then it’s complex. So it’s complex to bazedoxifene, which is in the class of SERMs. So it’s a third generation SERM. And how it differs from tamoxifen is, number one, it’s much more selective. So it doesn’t stimulate the endometrium. So that’s the big difference between bazedoxifene and tamoxifen. And that is why they kind of put these conjugated estrogens and the bazedoxifene together. So they kind of took out the progesterone that used to be part of combination estrogen and progesterone therapy and they exchanged it for the bazedoxifene. So that’s an easy way to think about it. Yeah, so it’s a new class of drugs. It’s actually called a TSEC. That’s what it is, the class of drugs. So it’s different from aromatase inhibitors and SERMs that it is a complex of estrogens and the bazedoxifene.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...